• Racura Oncology is presenting preclinical bisantrene findings at the Frontiers in Cancer Science conference in Singapore, running November 11-13, 2026.
• The active (E,E)-bisantrene form reduced MYC gene expression; light exposure converted it into less active forms, weakening its effects.
• The findings support development of RC220, a proprietary (E,E)-bisantrene formulation, across the EMILI, HARNESS and CPACS clinical programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Racura Oncology Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611120700PR_NEWS_USPR_____CN96183) on November 12, 2026, and is solely responsible for the information contained therein.